CTMX (CytomX Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

CTMX (CytomX Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

Mkt Cap$846M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$114M

Net Income (TTM)$28M

EPS (TTM)$0.42

Free Cash Flow (TTM)-$72M

Gross Margin100.0%

Op. Margin20.5%

Net Margin24.7%

FCF Margin-63.7%

P/S Ratio (TTM)7.4x

P/E Ratio (TTM)30.2x

YoY Rev Growth-10.3%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$20M	$20M	-$10M
Q1 23	$23M	$22M	-$6M
Q2 23	$25M	$23M	-$3M
Q3 23	$26M	$25M	$11M
Q4 23	$27M	$27M	-$606K
Q1 24	$41M	$41M	$12M
Q2 24	$25M	$25M	-$8M
Q3 24	$33M	$33M	$4M
Q4 24	$38M	$38M	$18M
Q1 25	$51M	$51M	$23M
Q2 25	$19M	$19M	-$1M
Q3 25	$6M	$6M	-$16M

Valuation

Quarter	P/S	P/E
Q4 22	15.9x	—
Q1 23	12.5x	—
Q2 23	10.6x	—
Q3 23	8.9x	—
Q4 23	8.4x	—
Q1 24	7.1x	51.2x
Q2 24	7.1x	76.4x
Q3 24	6.7x	61.2x
Q4 24	6.1x	26.6x
Q1 25	5.7x	20.3x
Q2 25	6.0x	17.6x
Q3 25	7.4x	30.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$1M	-$2M
Q1 23	$9M	$9M
Q2 23	-$25M	-$26M
Q3 23	-$18M	-$18M
Q4 23	-$22M	-$22M
Q1 24	-$26M	-$26M
Q2 24	-$20M	-$20M
Q3 24	-$21M	-$21M
Q4 24	-$20M	-$20M
Q1 25	-$21M	-$21M
Q2 25	-$16M	-$16M
Q3 25	-$16M	-$15M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$182K
Q1 23	$48K
Q2 23	$517K
Q3 23	$9K
Q4 23	$266K
Q1 24	$115K
Q2 24	$96K
Q3 24	$19K
Q4 24	$80K
Q1 25	$119K
Q2 25	$27K
Q3 25	$127K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	+2.0%	-35.6%
Q1 23	+159.9%	-29.1%
Q2 23	+92.4%	-34.6%
Q3 23	+136.7%	-62.6%
Q4 23	+32.2%	-8.2%
Q1 24	+76.4%	+2.2%
Q2 24	+1.6%	+19.6%
Q3 24	+26.7%	+91.8%
Q4 24	+43.2%	-25.0%
Q1 25	+22.8%	-5.1%
Q2 25	-25.7%	-40.6%
Q3 25	-82.2%	-25.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$0	0.0%
Q1 23	$2M	10.3%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$3M	9.6%
Q1 24	$2M	4.6%
Q2 24	$2M	7.5%
Q3 24	$2M	6.0%
Q4 24	$2M	4.9%
Q1 25	$2M	3.9%
Q2 25	$1M	7.7%
Q3 25	$2M	25.2%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$20M	$8M	—
Q1 23	$21M	—	$7M
Q2 23	$20M	—	$6M
Q3 23	$10M	—	$3M
Q4 23	$19M	$8M	—
Q1 24	$22M	$8M	—
Q2 24	$25M	$8M	—
Q3 24	$21M	$8M	—
Q4 24	$15M	$6M	—
Q1 25	$19M	$9M	—
Q2 25	$13M	$7M	—
Q3 25	$15M	$6M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$194M	$0	$194M
Q1 23	$56M	$148M	$205M
Q2 23	$58M	$123M	$181M
Q3 23	$26M	$168M	$194M
Q4 23	$17M	$157M	$175M
Q1 24	$36M	$114M	$150M
Q2 24	$43M	$94M	$137M
Q3 24	$41M	$77M	$118M
Q4 24	$38M	$63M	$101M
Q1 25	$48M	$32M	$80M
Q2 25	$49M	$109M	$158M
Q3 25	$34M	$109M	$144M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	66M	+0.5%
Q1 23	66M	+0.0%
Q2 23	67M	+0.4%
Q3 23	81M	+21.7%
Q4 23	67M	-16.9%
Q1 24	83M	+22.8%
Q2 24	85M	+2.7%
Q3 24	85M	+0.4%
Q4 24	80M	-6.0%
Q1 25	87M	+8.8%
Q2 25	129M	+48.1%
Q3 25	165M	+27.8%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 13	—	—
FY 14	—	—
FY 15	$119K	65
FY 16	$193K	78
FY 17	$779K	92
FY 18	$434K	137
FY 19	$364K	158
FY 20	$475K	144
FY 21	$214K	174
FY 22	$458K	116
FY 23	$843K	120
FY 24	$1M	119